The effects affirm conclusions drawn by Bagli et al. [1], who conducted a research that incorporated 10 patients diagnosed with CRAO who received HBOT. Together with acquiring 20 classes of HBOT, oral acetazolamide and topical beta-blockers were administered towards the patients for the earliest doa